eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | small cell carcinoma |
| Comorbidity | C0024115|lung disease |
| Sentences | 8 |
| PubMedID- 26134440 | Purpose: to investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (sclc) patients with pre-existing interstitial lung disease (ild). |
| PubMedID- 26288223 | Interstitial lung disease (ild) occurs in patients with non-small cell lung cancer receiving egfr inhibitors. |
| PubMedID- 25563718 | Purpose: the prognosis of non-small cell lung cancer (nsclc) patients with interstitial lung disease (ild) is unclear. |
| PubMedID- 25012241 | Background: non-small cell lung cancer (nsclc) patients with interstitial lung disease (ild) need to be approached carefully given the high incidence of pulmonary toxicity. |
| PubMedID- 19657749 | Interstitial lung disease in patients with small cell lung cancer. |
| PubMedID- 23750540 | Crizotinib-induced acute interstitial lung disease in a patient with eml4-alk positive non-small cell lung cancer and chronic interstitial pneumonia. |
| PubMedID- 21036764 | Background: since advanced non-small cell lung cancer (nsclc) patients with the interstitial lung disease (ild) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients. |
| PubMedID- 22233823 | Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. |
Page: 1